Search

Liquid side-streams from food industries can be processed and used in food applications and contribute to reduce the environmental footprint of industries. The goal of this study was to evaluate the effectiveness and applicability of protein and phosphorus separation processes, namely microfiltration, ultrafiltration and flocculation, using protein-rich process waters with low (LS) and high (HS) salt content from the processing of salted cod (Gadus morhua). The application of different flocculants (chitosan lactate and Levasil RD442) were evaluated at different concentrations and maturation periods (0, 1 or 3 h). The results showed that different flocculation treatments resulted in different recoveries of the nutrients from LS and HS. Proteins in LS could be most efficiently recovered by using Levasil RD442 0.25% and no maturation period (51.4%), while phosphorus was most efficiently recovered when using Levasil RD442 1.23% and a maturation period of 1 h (34.7%). For HS, most of its protein was recovered using Levasil RD442 1.23% and a maturation period of 1 h (51.8%), while phosphorus was recovered the most using Levasil 1.23% and no maturation period (47.1%). The salt contents allowed interactions through intermolecular forces with Levasil RD442. The ultrafiltration method was effective on HS since it recovered higher percentages of nutrients in the retentate phase (57% of the protein and 46% of the phosphorus) compared to LS.

Spindle cell/pleomorphic lipoma has a wide range of histologic appearances and frequently presents diagnostic difficulties. All but the most common cases can be easily confused for locally aggressive or malignant entities. Recently, a family of related tumors resembling SCPL but with unusual clinical features and an atypical and aggressive histologic appearance has been described under the umbrella term of atypical spindle cell pleomorphic lipomatous tumors (ASCPLT). Proper identification of these tumors is critical to prevent unwarranted aggressive surgical and medical therapy. This review focuses on the clinical and histopathologic features of SCL and ASCPLT as well as the challenging differential diagnoses these tumors present.

Bacteria often live in communities of mixed species embedded in a self-produced extracellular matrix of polysaccharides, proteins and DNA, termed biofilms. The BioFlux microfluidic flow system is useful for studying biofilm formation in different media under flow. However, analyzing the architecture and maturation of biofilms under flow requires a proper seeding, which can prove difficult when working with bacteria of different sizes, motile bacteria or aiming for a high number of replicates. Here we developed an efficient protocol that exploits viscosity tuning and seeding indicator dyes to improve seeding and allow for high-throughput examination and visualization of consistent mono- and mixed-species biofilm developments under flow.

Fibrous hamartoma of infancy (FHI) is a rare, benign lesion characterized as a tumor of myofibroblastic origin that has characteristic features of triphasic histology. FHI was first described in 1956 by Reye and formally named by Enzinger in 1965 [1-2]. The lesion is defined as a hamartoma due to the histologic presentation of disorganized mesenchymal, fibrous, and adipose tissue with absence of mitotic figures; this combination of derived tissue without evidence of anaplasia is diagnostic for FHI. These lesions typically arise as a single, solitary mass, are most commonly located on the extremities, trunk, sacrum, or scrotum and are typically 0.5 to 9.0 centimeters in size [3-4]. Only roughly 200 cases have been reported in the literature [3]. The majority of cases occur in young children; 91% of cases arise within the first year of life [4]. Males are more often affected in a ratio of 2.4:1 [4]. Roughly 20% of cases have been documented as congenital (3). Treatment is surgical excision, which is often curative; local recurrence is rare and incidence decreased by obtaining negative margins (8). We present a case of congenital FHI identified at birth.